Expression of fascin in Invasive mammary cancer - A study at a Tertiary care centre in Southern India


  • Uma Ramanathan
  • Lawrence D'Cruze
  • Thanka J.
  • Barathi G.
  • Vasugi G. A.
  • Susruthan M.
  • Kaviarasan K.



FASCIN, immunohistochemistry, invasive mammary cancer, triple negative, targeted therapy, node negative category


Introduction and Aim: Breast cancer is the commonest malignancy in women. Most women do not die of the primary tumor but from metastasis and local invasion. Augmented motility of cancer cells corroborates with greater metastatic potential, that is brought about by actin cytoskeleton. Fascin, a cytoplasmic F-actin-bundling protein that cross-links actin filaments and its overexpression is strongly associated with metastatic progression and poor prognosis. The present study aims to determine the fascin protein expression by immunohistochemistry in invasive breast carcinoma and to correlate the same with the existing prognostic factors.


Methods: Immunohistochemical expression of fascin in 100 cases of invasive mammary carcinoma was studied. Data collected was scored based on intensity and statistically analyzed using GNU-PSPP version 0.10 software. To determine significant clinico-pathological differences between fascin expression in positive and negative tumors, Pearson Chi-square test was used.


Results: It was noted that 22 of the 100 cases were positive with a score of 3 or more. A significant association of nodal status with fascin (p value <0.05) was noted. Higher proportion of fascin positive tumors were node negative. There was an inverse correlation between ER/PR/HER2 status and fascin positivity. The corresponding p values for ER, PR and HER2 with fascin were <0.05. On the contrary 12(57.15%) of the 21 triple negative cases were fascin positive. The p value was <0.001 indicating a significant correlation between molecular subtypes and fascin expression. A more of the fascin positive tumors fell in the triple negative category.


Conclusion: Higher proportion of fascin positive cases in the node negative category, an inverse correlation between fascin expression and individual ER/PR, HER2 expression and larger number of fascin positive cases in the triple negative category. These findings point an association of fascin with aggressive breast carcinomas.

Author Biographies

Uma Ramanathan

Department of Pathology, Sri Ramachandra Institute of Higher Education & Research, Chennai, Tamil Nadu, India

Lawrence D'Cruze

Department of Pathology, Sri Ramachandra Institute of Higher Education & Research, Chennai, Tamil Nadu, India

Thanka J.

Department of Pathology, Sree Balaji Medical College and Hospital, Chennai, Tamil Nadu, India

Barathi G.

Department of Pathology, Sri Ramachandra Institute of Higher Education & Research, Chennai, Tamil Nadu, India

Vasugi G. A.

Department of Pathology, Sri Ramachandra Institute of Higher Education & Research, Chennai, Tamil Nadu, India

Susruthan M.

Department of Pathology, Sri Ramachandra Institute of Higher Education & Research, Chennai, Tamil Nadu, India

Kaviarasan K.

Department of Biomedical Sciences, Faculty of Biomedical Sciences, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India


Ghebeh, H., Al-Khaldi, S., Olabi, S., Al-Dhfyan, A., Al- Mohanna, F., Barnawi, R., et al., Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway. Br J Cancer. 2014;111(8):1552-1561. DOI:

Wang, C.Q., Tang, C.H., Chang, H.T., Li, X.N., Zhao, Y.M., Su, C.M., et al., Fascin-1 as a novel diagnostic marker of triple negative breast cancer. Cancer medicine. 2016; 5(8):1983-1988. DOI:

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin D.M., et al., Cancer incidence and mortality worldwide: Sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5): E359- E386. DOI:

Leong, S.P.L., Shen, Z-Z, Liu T.J., Agarwal, G., Tajima, T., Paik, N.S., et al., Is Breast cancer the same disease in Asian and Western countries? World J Surgery. 2010;34(10):2308-2324. DOI:

Weiss, H.A., Devesa, S.S., Brinton, L.A. Laterality of breast cancer in the United States. Cancer Causes and Control. 1996;7(5):539-543. DOI:

Sughrue, T., Brody, J.P. Breast tumor laterality in the United States depends upon the country of birth but not race. PloS One. 2014;9(8): e103313. DOI:

Bao, J., Yu, K.D., Jiang, Y.Z., Shao, Z.M., Di, G.H. The effect of laterality and primary tumor site on cancer-specific mortality in breast cancer: a SEER population-based study. PloS one. 2014;9(4): e94815. DOI:

Sandhu, D.S., Sandhu, S., Karwasra, R.K., Marwah, S. Profile of breast cancer patients at a tertiary care hospital in north India. Indian journal of cancer. 2010;47(1):16-22. DOI:

Li, C.I., Moe, R.E., Daling, J.R. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Archives of Internal Medicine. 2003;163(18):2149-2153. DOI:

Li, C.I., Uribe, D.J., Daling, J.R. Clinical characteristics of different histologic types of breast cancer. British Journal of Cancer. 2005; 93(9):1046-1052. DOI:

Grothey, A., Hashizume, R., Sahin, A.A., McCrea, P.D. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. British journal of cancer. 2000;83(7):870-873. DOI:

Saxena, S., Rekhi, B., Bansal, A., Bagga, A., Murthy, N.S. Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India -A cross-sectional study. World Journal of Surgical Oncology. 2005;3: 67. DOI:

Yoder, B.J., Tso, E., Skacel, M., Pettay, J., Tarr, S., Budd, T., et al., The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor–negative breast cancer and a more aggressive clinical course. Clinical Cancer Research. 2005;11(1):186-92. DOI:

Dinshaw, K.A., Budrukkar, A.N., Chinoy, R.F., Sarin, R., Badwe, R., Hawaldar, R., et al., Profile of prognostic factors in 1022 Indian women with early-stage breast cancer treated with breast-conserving therapy. International Journal of Radiation Oncology Biology Physics. 2005;63(4):1132-1141. DOI:

Agarwal, G., Ramakant, P. Breast cancer care in India: the current scenario and the challenges for the future. Breast care. 2008;3(1):21-27. DOI:

Khokhar, A. Breast cancer in India: where do we stand and where do we go? Asian Pacific Journal of Cancer Prev. 2012; 13(10): 4861-4866. DOI:

Gandham, S.V., Singh, R., Gupta, S., Pawar, S.B., Pawar, R.S., Prabhudesai, S. Evaluation of ER, PR and HER-2 receptor expression in breast cancer patients presenting to a semi urban cancer centre in Western India. Journal of cancer research and therapeutics. 2014;10(1):26. DOI:

Li, C.I., Malone, K.E., Daling, J.R. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiology Biomarkers & Prevention. 2002;11(7):601-607.

Tamimi, R.M., Colditz, G.A., Hazra, A., Baer, H.J., Hankinson, S.E., Rosner, B., et al., Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. Breast cancer research and treatment. 2012;131(1):159-167. DOI:

Tan, V.Y., Lewis, S.J., Adams, J.C., Martin, R.M. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta - analysis. BMC medicine. 2013;11(1):52. DOI:

Al-Alwan, M., Olabi, S., Ghebeh, H., Barhoush, E., Tulbah, A., Al-Tweigeri, T., et al., Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PloS one. 2011;6(11): e27339. DOI:

Hashimoto, Y., Skacel, M., Lavery, I.C., Mukherjee, A.L., Casey, G., Adams, J.C. Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC cancer. 2006;6(1): 241. DOI:

Rodríguez-Pinilla, S.M., Sarrió, D., Honrado, E., Hardisson, D., Calero, F., Benitez, J., et al., Prognostic significance of basal-like phenotype and fascin expression in node- negative invasive breast carcinomas. Clinical cancer research. 2006;12(5):1533 -1539. DOI:




How to Cite

Ramanathan U, D’Cruze L, J. T, G. B, G. A. V, M. S, K. K. Expression of fascin in Invasive mammary cancer - A study at a Tertiary care centre in Southern India. Biomedicine [Internet]. 2022 Nov. 14 [cited 2022 Nov. 27];42(5):1023-8. Available from:



Original Research Articles

Plum Analytics